A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Phase II open label, multicenter study to evaluate the efficacy and safety of AK112
(PD-1/VEGF Bispecific) in patients with unresectable hepatocellular carcinoma (HCC).